IUCT, Pharmatest and CCTI boost Anticancer Active Compounds
The Consortium of IUCT, Pharmatest and CCTI has successfully ended the DISC-SCREEN project with a platform for the fast screening of new anticancer drugs. The Platform has been validated through the discovery of 15 active drug candidates
JPT, IUCT and LEITAT Announce Collaboration on the Development of Novel Biofocused Anticancer Therapies (NOBITAN)
Berlin, Germany, January 17, 2012 – JPT Peptide Technologies GmbH (JPT), a wholly-owned sub-sidiary of BioNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofo-cused targeting of nucleoside analogs linked to small cyclic peptidomimetics. The goal of the part-nership is to create novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile by selectively targeting inactive cytotoxic compounds toward tumor cells. The collaboration combines JPT’s proven and long term track record in executing peptide based hit identification and hit-to-lead projects with IUCT’s and LEITAT’s key expertise in biotechnological synthesis of nucleo-side analogs and activity screening studies.
Johan Diesenhoffer Premio Nobel